The impact of maternal obesity on inflammatory processes and consequences for later offspring health outcomes

Journal of Developmental Origins of Health and Disease

Volumn 8, Issue 5, 2017, Pages 529-540

  Segovia, S A ^a   Vickers, M H ^a   Reynolds, C M ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

developmental programming; inflammation; interventions; maternal obesity

Indexed keywords

AUTACOID;

COMPLICATION; FEMALE; FETUS DEVELOPMENT; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLISM; OBESITY; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME;

FEMALE; FETAL DEVELOPMENT; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; OBESITY; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME;

EID: 85016121128     PISSN: 20401744     EISSN: 20401752     Source Type: Journal    
DOI: 10.1017/S2040174417000204     Document Type: Conference Paper

References (147)

1. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 384, 766-781.
2. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med. 2007; 356, 213-215.
3. Cordain L, Eaton SB, Sebastian A, et al. Origins and evolution of the western diet: health implications for the 21st century. Am J Clin Nutr. 2005; 81, 341-354.
4. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003; 289, 76-79.
5. Wilson RM, Messaoudi I. The impact of maternal obesity during pregnancy on offspring immunity. Mol Cell Endocrinol. 2015; 418, 134-142.
6. Sebire NJ, Jolly M, Harris J, et al. Maternal obesity and pregnancy outcome: a study of 287 213 pregnancies in London. Int J Obes (Lond). 2001; 25, 1175-1182.
7. Catalano PM, Ehrenberg HM. The short-and long-term implications of maternal obesity on the mother and her offspring. BJOG. 2006; 113, 1126-1133.
8. Whitaker RC. Predicting preschooler obesity at birth: the role of maternal obesity in early pregnancy. Pediatrics. 2004; 114, e29-e36.
9. Boney CM, Verma A, Tucker R, et al. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005; 115, e290-e296.
10. Yu Z, Han S, Zhu J, et al. Pre-pregnancy body mass index in relation to infant birth weight and offspring overweight/obesity: a systematic review and meta-analysis. PLoS One. 2013; 8, e61627.
11. Vickers M. Developmental programming and transgenerational transmission of obesity. Ann Nutr Metab. 2014; 64, 26-34.
12. O'Reilly JR, Reynolds RM. The risk of maternal obesity to the long?term health of the offspring. Clin Endocrinol (Oxf). 2013; 78, 9-16.
13. King JC. Maternal obesity, metabolism, and pregnancy outcomes. Annu Rev Nutr. 2006; 26, 271-291.
14. Ramsay JE, Ferrell WR, Crawford L, et al. Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways. J Clin EndocrMetab. 2002; 87, 4231-4237.
15. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011; 121, 2111-2117.
16. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004; 89, 2548-2556.
17. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007; 117, 175-184.
18. Drolet R, Bélanger C, Fortier M, et al. Fat depot?specific impact of visceral obesity on adipocyte adiponectin release in women. Obesity. 2009; 17, 424-430.
19. Kim JK, Gavrilova O, Chen Y, et al. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem. 2000; 275, 8456-8460.
20. Ye J, Gao Z, Yin J, et al. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab. 2007; 293, E1118-E1128.
21. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112, 1796-1808.
22. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm. 2006; 74, 443-477.
23. Silha JV, Krsek M, Skrha JV, et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003; 149, 331-335.
24. Cnop M, Havel P, Utzschneider K, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003; 46, 459-469.
25. Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008; 168, 1617-1624.
26. Mongraw-Chaffin M, Foster MC, Kalyani RR, et al. Obesity severity and duration are associated with incident metabolic syndrome: evidence against metabolically healthy obesity from the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab. 2016; 101, 4117-4124.
27. Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter? Diabetes Care. 2013; 36, 2294-2300.
28. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesitylinked insulin resistance. Science. 1993; 259, 87-91.
29. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995; 95, 2409-2415.
30. Chen X, Xun K, Chen L, et al. TNF, a potent lipid metabolism regulator. Cell Biochem Funct. 2009; 27, 407-416.
31. Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-? function. Nature. 1997; 389, 610-614.
32. Lagathu C, Yvan-Charvet L, Bastard J, et al. Long-term treatment with interleukin-1? induces insulin resistance in murine and human adipocytes. Diabetologia. 2006; 49, 2162-2173.
33. McGillicuddy FC, Harford KA, Reynolds CM, et al. Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat dietinduced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes. 2011; 60, 1688-1698.
34. Kim J, Bachmann RA, Chen J. Interleukin?6 and insulin resistance. Vitam Horm. 2009; 80, 613-633.
35. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-?, in vivo 1. J Clin Endocrinol Metab. 1997; 82, 4196-4200.
36. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003; 278, 45777-45784.
37. Senn JJ, Klover PJ, Nowak IA, et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002; 51, 3391-3399.
38. Pedersen BK, Steensberg A, Schjerling P. Muscle?derived interleukin?6: possible biological effects. J Physiol (Lond). 2001; 536, 329-337.
39. Hu FB, Meigs JB, Li TY, et al. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004; 53, 693-700.
40. Kopp HP, Kopp CW, Festa A, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003; 23, 1042-1047.
41. Matthews V, Allen T, Risis S, et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia. 2010; 53, 2431-2441.
42. van Exel E, Gussekloo J, de Craen AJ, et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes : the Leiden 85-Plus Study. Diabetes. 2002; 51, 1088-1092.
43. Fiorentino DF, Zlotnik A, Mosmann TR, et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991; 147, 3815-3822.
44. Belo L, Santos-Silva A, Rocha S, et al. Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005; 123, 46-51.
45. Zhang L, Sugiyama T, Murabayashi N, et al. The inflammatory changes of adipose tissue in late pregnant mice. J Mol Endocrinol. 2011; 47, 157-165.
46. Madan JC, Davis JM, Craig WY, et al. Maternal obesity and markers of inflammation in pregnancy. Cytokine. 2009; 47, 61-64.
47. Retnakaran R, Hanley AJ, Raif N, et al. C-reactive protein and gestational diabetes: the central role of maternal obesity. J Clin Endocrinol Metab. 2003; 88, 3507-3512.
48. Basu S, Haghiac M, Surace P, et al. Pregravid obesity associates with increased maternal endotoxemia and metabolic inflammation. Obesity. 2011; 19, 476-482.
49. Kalagiri RR, Carder T, Choudhury S, et al. Inflammation in complicated pregnancy and its outcome. Am J Perinatol. 2016; 14, 1337-1356.
50. Arenz S, Rückerl R, Koletzko B, et al. Breast-feeding and childhood obesity-a systematic review. Int J Obes. 2004; 28, 1247-1256.
51. Panagos P, Vishwanathan R, Penfield-Cyr A, et al. Breastmilk from obese mothers has pro-inflammatory properties and decreased neuroprotective factors. J Perinatol. 2016; 36, 284-290.
52. Morigny P, Houssier M, Mouisel E, et al. Adipocyte lipolysis and insulin resistance. Biochimie. 2016; 125, 259-266.
53. Zambrano E, Nathanielsz PW. Mechanisms by which maternal obesity programs offspring for obesity: evidence from animal studies. Nutr Rev. 2013; 71(Suppl. 1), S42-S54.
54. Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001; 50, 707-709.
55. Collden G, Balland E, Parkash J, et al. Neonatal overnutrition causes early alterations in the central response to peripheral ghrelin. Mol Metab. 2015; 4, 15-24.
56. Huh SY, Rifas-Shiman SL, Taveras EM, et al. Timing of solid food introduction and risk of obesity in preschool-aged children. Pediatrics. 2011; 127, e544-e551.
57. Radaelli T, Uvena-Celebrezze J, Minium J, et al. Maternal interleukin-6: marker of fetal growth and adiposity. J Soc Gynecol Investig. 2006; 13, 53-57.
58. McCloskey K, Ponsonby A, Collier F, et al.The association between higher maternal pre?pregnancy body mass index and increased birth weight, adiposity and inflammation in the newborn. Pediatr Obes. 2016. https://doi.org/10.1111/ijpo.12187.
59. Gaillard R, Rifas?Shiman SL, Perng W, et al. Maternal inflammation during pregnancy and childhood adiposity. Obesity. 2016; 24, 1320-1327.
60. Farah N, Hogan AE, O'Connor N, et al. Correlation between maternal inflammatory markers and fetomaternal adiposity. Cytokine. 2012; 60, 96-99.
61. Toledo Baldi E, Dias Bóbbo V, Melo Lima M, et al. Tumor necrosis factor?alpha levels in blood cord is directly correlated with the body weight of mothers. Obes Sci Pract. 2016; 2, 210-214.
62. Danielsen I, Granström C, Rytter D, et al. Subclinical inflammation during third trimester of pregnancy was not associated with markers of the metabolic syndrome in young adult offspring. Obesity. 2014; 22, 1351-1358.
63. Onore CE, Schwartzer JJ, Careaga M, et al. Maternal immune activation leads to activated inflammatory macrophages in offspring. Brain Behav Immun. 2014; 38, 220-226.
64. Kirsten TB, Lippi LL, Bevilacqua E, et al. LPS exposure increases maternal corticosterone levels, causes placental injury and increases IL-1Beta levels in adult rat offspring: relevance to autism. PLoS One. 2013; 8, e82244.
65. Nilsson C, Larsson B, Jennische E, et al. Maternal endotoxemia results in obesity and insulin resistance in adult male offspring 1. Endocrinology. 2001; 142, 2622-2630.
66. Murabayashi N, Sugiyama T, Zhang L, et al. Maternal high-fat diets cause insulin resistance through inflammatory changes in fetal adipose tissue. Eur J Obstet Gyn R B. 2013; 169, 39-44.
67. Alfaradhi MZ, Kusinski LC, Fernandez-Twinn DS, et al. Maternal obesity in pregnancy developmentally programs adipose tissue inflammation in young, lean male mice offspring. Endocrinology. 2016; 157, 4246-4256.
68. Challier JC, Basu S, Bintein T, et al. Obesity in pregnancy stimulates macrophage accumulation and inflammation in the placenta. Placenta. 2008; 29, 274-281.
69. Zhu MJ, Du M, Nathanielsz PW, et al. Maternal obesity upregulates inflammatory signaling pathways and enhances cytokine expression in the mid-gestation sheep placenta. Placenta. 2010; 31, 387-391.
70. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995; 269, 543-546.
71. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J. 1998; 12, 57-65.
72. Lappas M, Permezel M, Rice GE. Leptin and adiponectin stimulate the release of proinflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue via nuclear factor-?B, peroxisomal proliferator-activated receptor-? and extracellularly regulated kinase 1/2. Endocrinology. 2005; 146, 3334-3342.
73. Schwartz MW, Peskind E, Raskind M, et al. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med. 1996; 2, 589-593.
74. Shankar K, Harrell A, Liu XL, et al. Maternal obesity at conception programs obesity in the offspring. Am J Physiol-Reg I. 2008; 294, R528-R538.
75. Oben JA, Mouralidarane A, Samuelsson AM, et al. Maternal obesity during pregnancy and lactation programs the development of offspring non-alcoholic fatty liver disease in mice. J Hepatol. 2010; 52, 913-920.
76. Sáinz N, González-Navarro CJ, Martínez JA, et al. Leptin signaling as a therapeutic target of obesity. Expert Opin Ther Targets. 2015; 19, 893-909.
77. Lihn AS, Bruun JM, He G, et al. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol. 2004; 219, 9-15.
78. Park K, Park KS, Kim M, et al. Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract. 2004; 63, 135-142.
79. Yamauchi T, Kamon J, Minokoshi Ya, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002; 8, 1288-1295.
80. Ohashi K, Parker JL, Ouchi N, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem. 2010; 285, 6153-6160.
81. Jones HN, Woollett LA, Barbour N, et al. High-fat diet before and during pregnancy causes marked up-regulation of placental nutrient transport and fetal overgrowth in C57/BL6 mice. FASEB J. 2009; 23, 271-278.
82. Aye IL, Rosario FJ, Powell TL, et al. Adiponectin supplementation in pregnant mice prevents the adverse effects of maternal obesity on placental function and fetal growth. Proc Natl Acad Sci U S A. 2015; 112, 12858-12863.
83. Saben J, Lindsey F, Zhong Y, et al.Maternal obesity is associated with a lipotoxic placental environment. Placenta. 2014; 35, 171-177.
84. Dosch NC, Guslits EF, Weber MB, et al. Maternal obesity affects inflammatory and iron indices in umbilical cord blood. J Pediatr. 2016; 172, 20-28.
85. Kroener L, Wang ET, Pisarska MD. Predisposing factors to abnormal first trimester placentation and the impact on fetal outcomes. Semin Reprod Med. 2016; 34, 27-35.
86. Hayes EK, Tessier DR, Percival ME, et al. Trophoblast invasion and blood vessel remodeling are altered in a rat model of lifelong maternal obesity. Reprod Sci. 2014; 21, 648-657.
87. Lager S, Jansson N, Olsson A, et al. Effect of IL-6 and TNF-? on fatty acid uptake in cultured human primary trophoblast cells. Placenta. 2011; 32, 121-127.
88. Huang L, Liu J, Feng L, et al. Maternal prepregnancy obesity is associated with higher risk of placental pathological lesions. Placenta. 2014; 35, 563-569.
89. Mark P, Sisala C, Connor K, et al. A maternal high-fat diet in rat pregnancy reduces growth of the fetus and the placental junctional zone, but not placental labyrinth zone growth. J DOHaD. 2011; 2, 63-70.
90. Mark P, Lewis J, Jones M, et al. The inflammatory state of the rat placenta increases in late gestation and is further enhanced by glucocorticoids in the labyrinth zone. Placenta. 2013; 34, 559-566.
91. Farley D, Choi J, Dudley D, et al. Placental amino acid transport and placental leptin resistance in pregnancies complicated by maternal obesity. Placenta. 2010; 31, 718-724.
92. Leon-Garcia SM, Roeder HA, Nelson KK, et al. Maternal obesity and sex-specific differences in placental pathology. Placenta. 2016; 38, 33-40.
93. Ditchfield A, Desforges M, Mills T, et al. Maternal obesity is associated with a reduction in placental taurine transporter activity. Int J Obes. 2014; 4, 557-564.
94. Dube E, Gravel A, Martin C, et al. Modulation of fatty acid transport and metabolism by maternal obesity in the human fullterm placenta. Biol Reprod. 2012; 87, 1-11.
95. Langley-Evans SC. Developmental programming of health and disease. Proc Nutr Soc. 2006; 65, 97-105.
96. Hanson MA, Gluckman PD. Early developmental conditioning of later health and disease: physiology or pathophysiology? Physiol Rev. 2014; 94, 1027-1076.
97. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol (1985). 2005; 98, 1154-1162.
98. Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among US adults. Epidemiology. 2002; 13, 561-568.
99. Vega CC, Reyes-Castro LA, Bautista CJ, et al. Exercise in obese female rats has beneficial effects on maternal and male and female offspring metabolism. Int J Obes. 2013; 4, 712-719.
100. Bae-Gartz I, Janoschek R, Kloppe CS, et al. Running exercise in obese pregnancies prevents IL-6 trans-signaling in male offspring. Med Sci Sports Exerc. 2016; 48, 829-838.
101. Tinius RA, Cahill AG, Strand EA, et al. Maternal inflammation during late pregnancy is lower in physically active compared with inactive obese women. Appl Physiol Nutr Metab. 2015; 41, 191-198.
102. Chen H, Simar D, Pegg K, et al. Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal overnutrition in rodents. Diabetologia. 2014; 57, 614-622.
103. Heliövaara M, Herz M, Teppo A, et al. Pioglitazone has antiinflammatory effects in patients with type 2 diabetes. J Endocrinol Invest. 2007; 30, 292-297.
104. Kalanderian A, Abate N, Patrikeev I, et al. Pioglitazone therapy in mouse offspring exposed to maternal obesity. Am J Obstet Gynecol. 2013; 208, 308 e1-7.
105. Desai N, Roman A, Rochelson B, et al. Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome. Am J Obstet Gynecol. 2013; 209, 136. e1-9.
106. Harris K, Desai N, Gupta M, et al. The effects of prenatal metformin on obesogenic diet-induced alterations in maternal and fetal fatty acid metabolism. Nutr Metab (Lond). 2016; 13, 55.
107. Salomäki H, Heinäniemi M, Vähätalo LH, et al. Prenatal metformin exposure in a maternal high fat diet mouse model alters the transcriptome and modifies the metabolic responses of the offspring. PLoS One. 2014; 9, e115778.
108. Chiswick CA, Reynolds RM, Denison FC, et al. Efficacy of metformin in pregnant obese women: a randomised controlled trial. BMJ Open. 2015; 5, e006854.
109. Chiswick C, Reynolds RM, Denison F, et al. Effect ofmetformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebocontrolled trial. Lancet Diabetes Endocrinol. 2015; 3, 778-786.
110. Novak TE, Babcock TA, Jho DH, et al. NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol. 2003; 284, L84-L89.
111. Neschen S, Morino K, Rossbacher JC, et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes. 2006; 55, 924-928.
112. Haghiac M, Yang X, Presley L, et al. Dietary omega-3 fatty acid supplementation reduces inflammation in obese pregnant women: a randomized double-blind controlled clinical trial. PLoS One. 2015; 10, e0137309.
113. Melody S, Vincent R, Mori T, et al. Effects of omega-3 and omega-6 fatty acids on human placental cytokine production. Placenta. 2015; 36, 34-40.
114. Moon R, Harvey N, Robinson S, et al. Maternal plasma polyunsaturated fatty acid status in late pregnancy is associated with offspring body composition in childhood. J Clin Endocrinol Metab. 2012; 98, 299-307.
115. Rytter D, Bech BH, Halldorsson T, et al. No association between the intake of marine n-3 PUFA during the second trimester of pregnancy and factors associated with cardiometabolic risk in the 20-year-old offspring. Br J Nutr. 2013; 110, 2037-2046.
116. Brei C, Stecher L, Much D, et al. Reduction of the n-6:n-3 longchain PUFA ratio during pregnancy and lactation on offspring body composition: follow-up results from a randomized controlled trial up to 5 y of age. Am J Clin Nutr. 2016; 103, 1472-1481.
117. Stratakis N, Gielen M, Chatzi L, et al. Effect of maternal n-3 long-chain polyunsaturated fatty acid supplementation during pregnancy and/or lactation on adiposity in childhood: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2014; 68, 1277-1287.
118. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002; 56, 365-379.
119. Simopoulos AP. An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. Nutrients. 2016; 8, 128.
120. Heerwagen MJ, Stewart MS, de la Houssaye BA, et al. Transgenic increase in n-3/n-6 fatty acid ratio reduces maternal obesity-associated inflammation and limits adverse developmental programming in mice. PLoS One. 2013; 8, e67791.
121. Hussain A, Nookaew I, Khoomrung S, et al. A maternal diet of fatty fish reduces body fat of offspring compared with a maternal diet of beef and a post?weaning diet of fish improves insulin sensitivity and lipid profile in adult C57BL/6 male mice. Acta Physiol (Oxf). 2013; 209, 220-234.
122. Bagley HN, Wang Y, Campbell MS, et al. Maternal docosahexaenoic acid increases adiponectin and normalizes IUGR-induced changes in rat adipose deposition. J Obes. 2013; 2013, 312153.
123. Muhlhausler BS, Miljkovic D, Fong L, et al. Maternal omega-3 supplementation increases fat mass in male and female rat offspring. Front Genet. 2011; 2, 48.
124. Zulkafli IS, Waddell BJ, Mark PJ. Postnatal dietary omega-3 fatty acid supplementation rescues glucocorticoid-programmed adiposity, hypertension, and hyperlipidemia in male rat offspring raised on a high-fat diet. Endocrinology. 2013; 154, 3110-3117.
125. Mark PJ, Wyrwoll CS, Zulkafli IS, et al. Rescue of glucocorticoid-programmed adipocyte inflammation by omega-3 fatty acid supplementation in the rat. Reprod Biol Endocrinol. 2014; 12, 1.
126. Chicco A, Creus A, Illesca P, et al. Effects of post-suckling n-3 polyunsaturated fatty acids: prevention of dyslipidemia and liver steatosis induced in rats by a sucrose-rich diet during pre-and post-natal life. Food Funct. 2016; 7, 445-454.
127. Balogun KA, Cheema SK. Dietary omega-3 fatty acids prevented adipocyte hypertrophy by downregulating DGAT-2 and FABP-4 in a sex-dependent fashion. Lipids. 2016; 51, 25-38.
128. Muhlhausler B, Gibson R, Makrides M. The effect of maternal omega-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation during pregnancy and/or lactation on body fat mass in the offspring: a systematic review of animal studies. Prostaglandins Leukot Essent Fatty Acids. 2011; 85, 83-88.
129. Mennitti LV, Oliveira JL, Morais CA, et al. Type of fatty acids in maternal diets during pregnancy and/or lactation and metabolic consequences of the offspring. J Nutr Biochem. 2015; 26, 99-111.
130. Kennedy A, Martinez K, Schmidt S, et al. Antiobesity mechanisms of action of conjugated linoleic acid. J Nutr Biochem. 2010; 21, 171-179.
131. Bauman D, Baumgard L, Corl B, et al. Biosynthesis of conjugated linoleic acid in ruminants. J Anim Sci. 2000; 77, 1-15.
132. Viladomiu M, Hontecillas R, Bassaganya-Riera J. Modulation of inflammation and immunity by dietary conjugated linoleic acid. Eur J Pharmacol. 2015; 785, 87-95.
133. Dhiman TR, Nam S, Ure AL. Factors affecting conjugated linoleic acid content in milk and meat. Crit Rev Food Sci Nutr. 2005; 45, 463-482.
134. Banni S. Conjugated linoleic acid metabolism. Curr Opin Lipidol. 2002; 13, 261-266.
135. West DB, Delany JP, Camet PM, et al. Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. Am J Physiol. 1998; 275, R667-R672.
136. Houseknecht KL, Heuvel JPV, Moya-Camarena SY, et al. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat. Biochem Biophys Res Commun. 1998; 244, 678-682.
137. Kritchevsky D, Tepper SA, Wright S, et al. Influence of graded levels of conjugated linoleic acid (CLA) on experimental atherosclerosis in rabbits. Nutr Res. 2002; 22, 1275-1279.
138. de Roos B, Rucklidge G, Reid M, et al. Divergent mechanisms of cis9, trans11-and trans10, cis12-conjugated linoleic acid affecting insulin resistance and inflammation in apolipoprotein E knockout mice: a proteomics approach. FASEB J. 2005; 19, 1746-1748.
139. Jaudszus A, Krokowski M, Mockel P, et al. Cis-9, trans-11-conjugated linoleic acid inhibits allergic sensitization and airway inflammation via a PPARgamma-related mechanism in mice. J Nutr. 2008; 138, 1336-1342.
140. Moloney F, Toomey S, Noone E, et al. Antidiabetic effects of cis-9, trans-11-conjugated linoleic acid may be mediated via anti-inflammatory effects in white adipose tissue. Diabetes. 2007; 56, 574-582.
141. Bassaganya-Riera J, Reynolds K, Martino-Catt S, et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology. 2004; 127, 777-791.
142. Belury MA, Moya-Camarena SY, Lu M, et al. Conjugated linoleic acid is an activator and ligand for peroxisome proliferator-activated receptor-gamma (PPAR gamma). Nutr Res. 2002; 22, 817-824.
143. Cheng W, Lii C, Chen H, et al. Contribution of conjugated linoleic acid to the suppression of inflammatory responses through the regulation of the NF-?B pathway. J Agric Food Chem. 2004; 52, 71-78.
144. Reynolds CM, Loscher CE, Moloney AP, et al. Cis-9, trans-11-conjugated linoleic acid but not its precursor trans-vaccenic acid attenuate inflammatory markers in the human colonic epithelial cell line Caco-2. Br J Nutr. 2008; 100, 13-17.
145. Reynolds CM, Draper E, Keogh B, et al. A conjugated linoleic acid-enriched beef diet attenuates lipopolysaccharide-induced inflammation in mice in part through PPARgamma-mediated suppression of toll-like receptor 4. J Nutr. 2009; 139, 2351-2357.
146. Park Y, Storkson JM, Albright KJ, et al. Evidence that the trans-10, cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids. 1999; 34, 235-241.
147. Segovia SA, Vickers MH, Zhang XD, et al. Maternal supplementation with conjugated linoleic acid in the setting of diet-induced obesity normalises the inflammatory phenotype in mothers and reverses metabolic dysfunction and impaired insulin sensitivity in offspring. J Nutr Biochem. 2015; 26, 1448-1457.